The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.
The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM. Oncogene (2003 Oncogene ( ) 22, 919-923. doi:10.1038 Keywords: ETS; heparanase promoter; tumor metastasis Tumor cell invasion and metastasis is the hallmark of malignancy. It has been the nightmare to cancer treatment. Thus, investigation on tumor metastasis has become the last frontier for cancer research (Hanahan and Weinberg, 2000) . A greater understanding of the molecular mechanism of complex process of tumor metastasis will help oncologists plan effective therapeutic strategy against metastatic cancers.
The essential processes needed for tumor metastasis are neoangiogenesis (Folkman, 1997) , remodeling of extracellular matrix (ECM), and degradation of basement membrane (BM) (Kohn and Liotta, 1995) . Previous attentions were focused on serine and cysteine proteases, and matrix metalloproteinases (MMP) (Kohn and Liotta, 1995; Werb, 1997) . These enzymes were known not only to breakdown tissue barriers so that tumor cells can invade through stroma and blood vessels, but they also participate in angiogenesis (Werb, 1997) . These enzymes can also cleave membrane bound pro forms growth factors thus releasing peptides that are mitogens for tumor and endothelial cells (Eccles, 1999) . In addition to the substrates of MMP in BM and ECM-collagens, lamins, fibronectins, and vitronectins, other main components are glycosaminoglycans of which heparin sulfate proteoglycan (HSPG) is the chief component. HSPGs are composed of a protein core covalently linked to glycosaminoglycan chains that interact closely with other ECM components (Dempsey et al., 2000) .
The heparanase (Hpa) that degrades the HS side chains of HSPGs is found mainly in platelets, placental trophobasts, and leukocytes (Hoogewerf et al., 1995; Freeman and Parish, 1998) . Therefore in tumor metastasis, the normal physiological functions of proteases and Hpa in embryogenesis, wound healing, tissue repair, and inflammation appear to be highjacked by tumor cells (Carmeliet and Jain, 2000) .
In addition to its ability to breakdown ECM and BM like MMP does, the Hpa is also involved in regulation of growth factor and cytokine activities. For example, the basic fibroblast growth factor (bFGF) and other heparin-binding growth factors are sequestered by heparin sulfate, providing a localized, readily available reservoir. They can be released by Hpa to activate cells. Likewise, the urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA) can also be released by Hpa to participate in the mitogenic cascades. It is also possible that Hpa can help to release tissuespecific growth factors that may be involved in organselective sites for metastatic cancer cells (Carmeliet and Jain, 2000) .
Although the functions of Hpa have been known for some time, perhaps because of its instability and the lack of effective assay system, the Hpa gene has been successfully cloned only 2 years ago (Hulett et al., 1999; Vlodavsky et al., 1999; Dong et al., 2000) . This, nevertheless, will facilitate the molecular analysis of this gene. One of the important unanswered questions is what is the molecular basis of the enhanced Hpa activity in metastatic cancer cells as compared with nonmetastatic cancer cells and normal cells. To answer this question, we have isolated Hpa regulatory sequences from a BAC clone that contains the Hpa locus and analysed the promoter activities of various deletion constructs of this regulatory sequences ( Figure 1a ). As shown in Figure 1b , most of the promoter activities were observed in the 598bp PstI/SacI promoter construct. The full-length EcoRl/SacI construct showed moderate promoter activity, whereas the smallest BamHI/SacI construct showed least promoter activities. Sequences analysis of the Hpa promoter showed that besides other putative transcription factor binding site, for example, GC box (for Spl), there were four ETS transcription factor binding sites.
The results from Figure 1b indicated that the two ETS binding sites near the transcription initiation site were not functional by themselves because they showed least promoter activities, whereas the two other ETS binding sites (near the 5 0 of the 598 bp construct) possess most of Hpa promoter activities. These two sites were different from the ones reported for the GA binding transcription factors for Hpa promoter (Jiang et al., 2002) . To test whether ETS transcription factors can transactivate the Hpa promoter, the PstI/SacI promoter construct was cotransfected with vectors expressing ETS1, ETS2, PEA3, or ER81 into MDA231 cells, and reporter activities were analysed. As shown in Figure 2 , after correction for the pGL3, pcDNA3 (in which PEA3 and ER81 cDNA were inserted), and pSG (in which ETS1 and ETS2 cDNA were inserted) controls, all the ETS family transcription factors tested could transactivate the Hpa promoter. Among the transcription factors tested, ETS1 appeared better than others to upregulate the Hpa gene activity.
The effect of ETS1, ETS2, PEA3, and ER81 was then tested on different Hpa promoter constructs. As shown in Figure 3 most of the transactivation activities were observed in the PstI/SacI fragment. The BamHI/SacI fragment although containing two ETS binding sites showed little transactivation effect by the ETS transcription factors. These results suggested that the two ETS binding sites between the PstI and BamHI sites were active and functional, whereas the two other ETS binding sites in the BamHI/SacI fragment may be inert and could not respond to the ETS transcription factors.
To further demonstrate the ETS binding sites between the PstI and BamHI sites on the Hpa promoter are functional, the two binding sites were mutagenized to create mutants Ml and M2 promoter constructs, respectively. The consensus sequences for the ETS binding motif on these two sites were abolished. As shown in Figure 4a , Ml or M2 mutation of the ETS binding site on either the EcoRI/SacI or PstI/SacI Hpa promoter drastically reduced the response to the transactivation effect of ETS1 transcription factor. These results provided further evidence that the two ETS binding sites between the PstI and BamHI sites of the Hpa promoter play an important role in regulating the expression of the Hpa gene. Restriction enzymes Hind lll, PstI, and BamHI were used to digest 1.5 kb EcoRI/SacI DNA of human Hpa promoter. These DNA fragments were inserted into reporter plasmid pGL3. The bold arrow indicated direction of transcription and the small arrow indicated the transcription initiation. The ETS binding sites were indicated with small squares. (b) Activity of various constructs of human Hpa promoter. Each reporter constructs (2 mg) was transfected into MDA231 cells. At 48 h after transfection, cells were lysed with reporter lysis buffer. The luciferase activities were measured for firefly and Renilla luciferase using the Dual Luciferase Reporter assay system (Promega) and a luminometer. The luciferase activity of control plasmid pGL3 was normalized as one and activities of various promoter constructs were expressed as folds of the control Figure 2 Effect of transcription factors of ETS family on the activity of the PstI/SacI human Hpa promoter. Plasmid vectors (2 mg) expressing ETS1, ETS2, PEA3, and ER81 were cotransfected with PstI/SacI reporter construct into MDA231 and analysed for reporter activities as for Figure 1b . The activities were normalized by subtracting contribution from control plasmids: pcDNA3 (in which PEA3 and ER81 cDNAs were inserted) and pSG (in which ETS1 and ETS2 cDNAs were inserted) Previous experiments showed that two of the ETS binding sites on the Hpa promoter were functional and can be transactivated by ETS1, ETS2, PEA3, and ER81. To further prove that ETS transcription factors can activate Hpa promoter, we construct dominant-negative mutant of ETS2 in which only the ETS DNA binding domain was inserted into expression vector pcDNA3 to form the construct pcDNA3/ETS2-DN. The ETS-2 DN can effectively abrogate the transactivation activity of wild-type ETS2 on the Hpa gene (Figure 4b ). The other dominant-negative constructs of ETS family transcription factor behaved the similar way (data not shown). These results strongly indicated that ETS family transcription factors play important regulatory function on the Hpa gene.
Neoplasia can be regarded as a result of failure in mechanisms in mediating cell-cell interactions with its consequential loss of balance to maintain cell shape and polarity. The perturbation of normal cellular regulatory processes will end up the death of cell through apoptosis, or if involved in developmental process may deform the organism, or the appearance of cancer cells (Hanahan and Weinberg, 2000) . Regardless of which path normal cells take to become cancer cell, the outcome is the same, that is, the appearance of group of cancer cells surrounded by normal tissues. Eventually, these cancer cells will invade and break out the adjacent tissue confinement, and travel to distant sites (in most cases preferential) where they establish new tumor colony. For the cancer cells to become invasive and metastatic, concerted processes of activation of epithelial mesenchymal transition (EMT) (Arias, 2001) , remodeling of ECM (Kohn and Liotta, 1995), and migration of cancer cells to distant specific sites (Nicolson, 1993) have to take place.
The molecular basis behind these processes remains to be illustrated. Certain transcription factors appear to play a dominant role in regulating genes related to metastasis. Previously, we showed that PEA3 can transactivate and upregulate vimentin gene in metastatic breast cancer cells (Chen et al., 1996) . When E1AF/ PEA3 was transfected into human nonsmall cell lung cancer cells, it was found that this transcription factor would increase the motility and invasiveness of the transfected cancer cells (Hiroumi et al., 2001) . These results suggested that transcription factors of ETS/ PEA3 family play an important role in activation of EMT.
In the remodeling of ECM, the ECM proteins are degraded by MMP, adamylysin-related membrane proteinases, or tissue serine proteinases (Werb, 1997) . Most of these enzymes are tightly regulated at the invasion front of tumor cells. The activation of the ECM-degrading enzymes is regulated by transcription factors, especially those of the ETS family: MMP and stromylysin by ETS1, ETS2, and PEA3 (Buttice and Kurkinen, 1993; Higashino et al., 1995) .
Besides the ECM proteins, another important component in ECM is glycosaminoglycans, mainly HSPG. HSPGs are covalently linked protein glycosaminoglycan conjugates found in ECMs. They play critical roles in cell-cell and cell-matrix interactions (Dempsey et al., 2000) . Heparin sulfate also tethers chemokines and growth factors to the matrix as storage depots for the bioactive signaling molecules. Thus, enzymes that specifically degrade HSPGs will also play a key role in remodeling ECM. One of these enzymes is Hpa. Unlike MMP, which is produced by the surrounding normal cells near the invasion front of the tumor cells, the Hpa gene was found to be upregulated by the metastatic cancer cells (Hulett et al., 1999; Vlodavsky et al., 1999) . Thus, activation of Hpa in cancer cells will turn them into more invasive metastatic cancer cells. Illustration of the regulation of Hpa activation will yield valuable information on the mechanism of tumor metastasis.
Our analysis of the regulatory sequences of human Hpa gene showed that the positive regulatory elements are within the 598 bp PstI/SacI fragment. Since the SacI site is about 30 bp downstream from the transcription initiation site, the most active cis-element is between the PstI site and transcription start site. Within the 598 bp construct, we found four ETS transcription factor binding sites. The two near the 3 0 portion of this construct appeared to have much less or no function since the smallest construct, the 230 bp BamHI/SacI showed little or background level of reporter activities. This was further proven by experiments on the failure of various transcription factors of ETS family to transactivate the reporter activities of the BamHI/ SacI construct.
In contrast, the two other ETS binding sites at the 5 0 portion of the PstI/SacI promoter construct are functional. The four transcription factors (ETS1, ETS2, PEA3, and ER81) of ETS family tested on these two sites all showed transactivation of the reporter. Among these four transcription factors, ETS1 and ETS2 showed the most potency. To further prove the importance of these two ETS binding sites in upregulating the human Hpa gene, these sites were mutated to abrogate the consensus ETS binding sequences. The mutated promoter constructs failed to respond to exogenous ETS1 transcription factor. In addition, the dominant-negative ETS2 transcription factor (i.e. it contains only DNA binding domain) can abrogate the transactivating activity of ETS2, further proving the importance of ETS transcription factors on upregulation of Hpa gene. These results strongly indicated that the two ETS binding sites near the 5 0 portion of the PstI/SacI human Hpa promoter are functionally important in upregulating Hpa expression. Our results are similar to recently published report that one of the ETS family transcription factor GABP can regulate Hpa gene expression (Jiang et al., 2002) . However, comparison of their results with data presented here indicated that the ETS1 and ETS2 are more potent than GABP in transactivating Hpa gene. In addition, these two ETS binding sites appeared to need the cooperation of GC box and SpI transcription factor to exert their regulatory function on the Hpa promoter (Jiang et al., 2002) .
In addition to the positive regulation of ETS transcription factors on the human Hpa gene, there may exist some negative regulatory cis-elements within the 500 bp Hind lll/PstI sequence of the Hpa promoter. It is very likely that with more detailed and refined deletion analysis of the regulatory sequences of the human Hpa gene, we will be able to find more positive and negative cis-elements and to identify their respective transcription factors that control the expression of the Hpa gene.
Taking together, the results presented here with the previous reports about the effects of transcription factors of ETS family on activation of EMT (Chen et al., 1996; Hiroumi et al., 2001 ) and on the activation of genes involved in the remodeling of ECM (Buttice and Kurkinen, 1993; Higashino et al., 1995) strongly suggested that the ETS transcription factors play a prominent role in the process of driving cancer cells toward metastasis. 0 -GAGAG-GAAG-3 0 was changed into 5 0 -GAGCTCAAG-3 0 ) and M2 (the site 5 0 -GTCAGGAAG-3 0 was changed into 5 0 -GTCGACAAG-3 0 ) on either EcoRI/SacI or PstI/SacI Hpa promoter constructs were cotransfected with ETS1 expression vector and analysed for the reporter activities. (b) Effect of dominant-negative ETS-2 on transactivation of Hpa promotor by wild-type ETS2. pcDNA/ ETS2-DN (1, 2, and 4 mg) (which contained only ETS2 DNA binding domain) were cotransfected with wild-type ETS2 expression vector (2 mg) and PstI/SacI Hpa reporter construct (Pst/SacLuc) (2 mg) into MDA231 cells and analysed for the luciferase activities similar to those in Figure 3 
